12th May 2005 15:00
12 May 2005Shire Pharmaceuticals Group plc (the "Company")The Company announces that on 11 May 2005 The Honourable James A. Grant, P.C.,C.M., Q.C., a non-executive director of the Company, exercised an optiongranted to him under the BioChem Pharma Stock Option Plan and acquired 31,859ordinary shares of ‚£0.05p each in the Company at an option price of ‚£2.50p pershare.As a result of this transaction The Honourable James Grant has an interest,excluding unexercised share options, in 68,269 ordinary shares of ‚£0.05p eachin the Company.T MayCompany SecretaryFor further information please contact:Investor Relations Clƒ©a Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing projects and marketing products in theareas of central nervous system (CNS), gastrointestinal (GI), and renaldiseases. Shire has operations in the world's key pharmaceutical markets (US,Canada, UK, France, Italy, Spain and Germany) as well as a specialist drugdelivery unit in the US.For further information on Shire, please visit the Company's website: www.shire.com.Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDShire Pharmaceuticals Group PLCRelated Shares:
Shire